SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are receiving attention following a strong fiscal first-quarter earnings report that featured cloud infrastructure revenue growth and a record backlog, with the community debating the company's long-term AI-driven growth potential versus its debt and capital expenditure levels. Traders are divided on whether the earnings beat will catalyze a sustained rally or be offset by macro-economic pressures ahead of key inflation data.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as crude oil prices surge to multi-year highs, driven by heightened geopolitical tensions in the Middle East and concerns over supply disruptions. Traders are actively debating whether this momentum will continue toward higher resistance levels or if a sharp reversal is imminent due to potential geopolitical deal-making or market overextension.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending as investors weigh strong fiscal third-quarter results—marked by revenue and earnings beats and increased share buybacks—against a softer-than-expected fourth-quarter revenue outlook. While some traders express optimism regarding the company's AI-driven ARR growth and dominant market position, others remain skeptical about the impact of artificial intelligence on its long-term competitive moat and recent leadership transition.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as traders position for upcoming CPI inflation data, with sentiment pressured by rising Treasury yields and surging oil prices stemming from geopolitical tensions. Market participants remain divided, debating whether the index will experience a short-term rebound or a deeper correction based on the volatility around the inflation print and potential Federal Reserve interest rate adjustments.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

The conversation is dominated by optimism regarding recent insider buying from the CEO and speculative, ongoing interest from activist investors, despite skepticism from some traders who feel the CEO's share purchase was too small. While retail sentiment remains divided, many are focused on the stock's recent rebound, viewing the current price as an opportunity to scale into positions for long-term growth.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is experiencing increased volatility and trading volume as investors debate its long-term viability in the nuclear energy sector, with sentiment divided between those optimistic about its regulatory approvals and those concerned by persistent earnings misses and dilutive share offerings. Much of the conversation is centered on the company's potential to secure data center energy contracts and the broader industry tailwinds surrounding small modular reactors.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is facing significant market volatility and selling pressure following the release of Phase 3 IZAR-1 trial data, which some investors characterize as underwhelming due to a perceived lack of clear clinical superiority over existing therapies. While the community remains divided between those citing best-in-class potential for sonelokimab in hidradenitis suppurativa and those frustrated by management's dilution strategy and lack of clear communication, speculation regarding a potential buyout or long-term commercialization remains the primary driver of investor interest.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing polarized sentiment as traders debate whether recent volatility represents a 'pump and dump' scheme or healthy consolidation ahead of future infrastructure developments and institutional adoption. While some community members are actively accumulating based on long-term conviction in the project's blockchain utility, others remain highly skeptical, citing consistent price declines, concerns regarding dilution, and frustration with stagnant project news.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is facing continued downward pressure as investors weigh concerns over intensified competition from Eli Lilly, patent cliffs, and analyst downgrades against the company's valuation and the expansion of its oral weight-loss franchise.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is trending as investors monitor ongoing pilot plant progress and the company's recent expansion of its Hydrochemolytic Technology applications into synthetic turf recycling, alongside discussions regarding institutional accumulation and the potential for commercial scalability. While supporters point to strong technical setups and long-term potential in circular economy markets, some skeptics remain vocal, questioning the company's long-term transparency and the economic viability of its technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INmune Bio (INMB) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

INmune Bio (INMB) Q4 2025 Earnings Transcript

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19, 2026 Equity Insider News...

INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial?

Equity

The FDA meeting minutes suggest INmune Bio’s late-stage Alzheimer’s trial design is on track.

INmune Bio (NASDAQ:INMB) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised INmune Bio from a "sell" rating to a "hold" rating in a research note on Sunday...

Praetorian PR LLC Sells 863,000 Shares of INmune Bio, Inc. $INMB

Praetorian PR LLC lowered its stake in INmune Bio, Inc. (NASDAQ:INMB - Free Report) by 99.3% in the second quarter, according to the company in its most recent disclosure with the Securities and...

INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

INmune Bio (INMB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

INmune Bio (INMB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

INmune  slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss

Investing.com --  INmune Bio  (NASDAQ:INMB) shares fell another 6% to about $2.17 on Tuesday after brokerages downgraded the stock, saying failure of the company’s experimental Alzheimer’s drug XPro in a mid‑stage trial sharply weakens its investment case.

INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial

The primary endpoint of the study was not met in the intent-to-treat population, the company said. 

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

INmune Bio Inc

Bullish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Current Price	$2.31
Prev Close	$2.46
Open	$2.43
Dividend Yield	0.00%
50-Day Moving Average	$2.04
Beta	1.73
Avg. Volume	386,089.87
PE Ratio	-3.34

52-Week High	$2.60
52-Week Low	$1.09
Market Capitalization	$68.27M
EPS (Annual)	-$1.86
Price to Book	3.02
Revenue Per Employee	$2,380.95

Feed

News

Sentiment

Earnings

Fundamentals

Info

INMB Fundamentals